| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyCellularComponent | neuron to neuron synapse | 1.78e-04 | 523 | 22 | 5 | GO:0098984 | |
| GeneOntologyCellularComponent | postsynaptic density | 1.15e-03 | 451 | 22 | 4 | GO:0014069 | |
| GeneOntologyCellularComponent | postsynaptic density, intracellular component | 1.21e-03 | 49 | 22 | 2 | GO:0099092 | |
| GeneOntologyCellularComponent | asymmetric synapse | 1.41e-03 | 477 | 22 | 4 | GO:0032279 | |
| GeneOntologyCellularComponent | postsynaptic specialization, intracellular component | 1.57e-03 | 56 | 22 | 2 | GO:0099091 | |
| GeneOntologyCellularComponent | postsynaptic specialization | 1.72e-03 | 503 | 22 | 4 | GO:0099572 | |
| Domain | fn3 | 1.41e-02 | 162 | 21 | 2 | PF00041 | |
| Domain | FN3 | 1.81e-02 | 185 | 21 | 2 | SM00060 | |
| Domain | Ig_I-set | 1.90e-02 | 190 | 21 | 2 | IPR013098 | |
| Domain | I-set | 1.90e-02 | 190 | 21 | 2 | PF07679 | |
| Domain | FN3 | 2.08e-02 | 199 | 21 | 2 | PS50853 | |
| Pubmed | 1.40e-07 | 1487 | 22 | 9 | 33957083 | ||
| Pubmed | 1.15e-06 | 3 | 22 | 2 | 29617048 | ||
| Pubmed | 1.37e-05 | 9 | 22 | 2 | 29180573 | ||
| Pubmed | 1.70e-05 | 529 | 22 | 5 | 14621295 | ||
| Pubmed | Functional analysis of candidate genes from genome-wide association studies of hearing. | 5.16e-05 | 17 | 22 | 2 | 31927188 | |
| Pubmed | 5.17e-05 | 1116 | 22 | 6 | 31753913 | ||
| Pubmed | 1.87e-04 | 32 | 22 | 2 | 26142281 | ||
| Pubmed | 2.24e-04 | 35 | 22 | 2 | 30940800 | ||
| Pubmed | Proteomic and yeast 2-hybrid screens to identify PTEN binding partners. | 3.81e-04 | 226 | 22 | 3 | 37839992 | |
| Pubmed | Analyses of shared genetic factors between asthma and obesity in children. | 4.06e-04 | 47 | 22 | 2 | 20816195 | |
| Pubmed | 6.18e-04 | 1139 | 22 | 5 | 36417873 | ||
| Cytoband | Ensembl 112 genes in cytogenetic band chr11q23 | 4.96e-03 | 220 | 22 | 2 | chr11q23 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr17p13 | 1.18e-02 | 346 | 22 | 2 | chr17p13 | |
| GeneFamily | Fibronectin type III domain containing | 5.69e-03 | 160 | 13 | 2 | 555 | |
| GeneFamily | Blood group antigens|CD molecules|I-set domain containing|Immunoglobulin like domain containing | 5.76e-03 | 161 | 13 | 2 | 593 | |
| Coexpression | GSE6674_UNSTIM_VS_ANTI_IGM_AND_CPG_STIM_BCELL_DN | 1.74e-05 | 199 | 21 | 4 | M6926 | |
| Coexpression | PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP | 2.19e-05 | 211 | 21 | 4 | M12225 | |
| Coexpression | SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_UP | 4.74e-05 | 13 | 21 | 2 | M2267 | |
| Coexpression | STEARMAN_LUNG_CANCER_EARLY_VS_LATE_UP | 1.42e-04 | 128 | 21 | 3 | M4925 | |
| Coexpression | STEARMAN_LUNG_CANCER_EARLY_VS_LATE_UP | 1.62e-04 | 134 | 21 | 3 | MM748 | |
| Coexpression | BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_DN | 3.05e-04 | 166 | 21 | 3 | M6110 | |
| Coexpression | GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP | 3.50e-04 | 174 | 21 | 3 | M1113 | |
| Coexpression | GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP | 3.68e-04 | 177 | 21 | 3 | MM479 | |
| Coexpression | YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_15 | 3.79e-04 | 36 | 21 | 2 | M2687 | |
| Coexpression | YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_15 | 3.79e-04 | 36 | 21 | 2 | MM1284 | |
| Coexpression | XIE_TRASTUZUMAB_CARDIOTOXICITY_CIRCRNA_GENES | 4.68e-04 | 40 | 21 | 2 | MM17488 | |
| Coexpression | GSE15659_CD45RA_NEG_CD4_TCELL_VS_RESTING_TREG_UP | 4.89e-04 | 195 | 21 | 3 | M3551 | |
| Coexpression | GSE15659_CD45RA_NEG_CD4_TCELL_VS_NONSUPPRESSIVE_TCELL_UP | 4.96e-04 | 196 | 21 | 3 | M3553 | |
| Coexpression | GSE15659_CD45RA_NEG_CD4_TCELL_VS_ACTIVATED_TREG_UP | 5.03e-04 | 197 | 21 | 3 | M3555 | |
| Coexpression | GSE6875_TCONV_VS_FOXP3_KO_TREG_DN | 5.26e-04 | 200 | 21 | 3 | M6802 | |
| Coexpression | GSE17721_POLYIC_VS_GARDIQUIMOD_16H_BMDC_DN | 5.26e-04 | 200 | 21 | 3 | M4032 | |
| Coexpression | GSE2770_UNTREATED_VS_TGFB_AND_IL4_TREATED_ACT_CD4_TCELL_2H_UP | 5.26e-04 | 200 | 21 | 3 | M6016 | |
| Coexpression | GSE41978_WT_VS_ID2_KO_KLRG1_LOW_EFFECTOR_CD8_TCELL_UP | 5.26e-04 | 200 | 21 | 3 | M9553 | |
| Coexpression | LIU_PROSTATE_CANCER_DN | 5.74e-04 | 493 | 21 | 4 | M19391 | |
| Coexpression | SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_DN | 5.93e-04 | 45 | 21 | 2 | M8813 | |
| Coexpression | ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_DN | 5.93e-04 | 45 | 21 | 2 | M950 | |
| Coexpression | IKEDA_MIR133_TARGETS_UP | 5.93e-04 | 45 | 21 | 2 | MM929 | |
| Coexpression | YANG_BREAST_CANCER_ESR1_LASER_DN | 6.47e-04 | 47 | 21 | 2 | M11078 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Paraxial Mesoderm_top-relative-expression-ranked_2500_k-means-cluster#3 | 4.15e-05 | 730 | 20 | 6 | Facebase_RNAseq_e8.5_Paraxial Mesoderm_2500_K3 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#5 | 2.96e-04 | 658 | 20 | 5 | Facebase_RNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Mandibular Arch_top-relative-expression-ranked_2500_k-means-cluster#5 | 3.64e-04 | 688 | 20 | 5 | Facebase_RNAseq_e10.5_Mandibular Arch_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#4 | 4.51e-04 | 721 | 20 | 5 | Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_2500_K4 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Facial Mesenchyne_top-relative-expression-ranked_2500_k-means-cluster#5 | 4.54e-04 | 722 | 20 | 5 | Facebase_RNAseq_e9.5_Facial Mesenchyne_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_2500_k-means-cluster#5 | 4.84e-04 | 732 | 20 | 5 | Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#5 | 5.18e-04 | 743 | 20 | 5 | Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_2500_K5 | |
| CoexpressionAtlas | Stromal Cells, Ep.MEChi.Th, CD45-EpCAm+Ly51-MHCIIhi, Thymus, avg-1 | 5.24e-04 | 411 | 20 | 4 | GSM854302_500 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_2500_k-means-cluster#2 | 5.31e-04 | 747 | 20 | 5 | Facebase_RNAseq_e9.5_Maxillary Arch_2500_K2 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#2 | 5.31e-04 | 747 | 20 | 5 | Facebase_RNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_2500_K2 | |
| CoexpressionAtlas | facebase_RNAseq_e14.5_palate_poster_distal_ERK2_WT_2500_K1 | 5.39e-04 | 1166 | 20 | 6 | facebase_RNAseq_e14.5_palate_poster_distal_ERK2_WT_2500_K1 | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_perichondrial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.17e-08 | 200 | 21 | 5 | a4ec0e80f5422b91b85264a9bb74568dd577e285 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.74e-06 | 190 | 21 | 4 | 45df8fee00f8949937863159d7aa042e72748d9b | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.78e-06 | 191 | 21 | 4 | b13229bb7f3713a392271aaf5dbae3edd1b9fe5a | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.82e-06 | 192 | 21 | 4 | 6f4ef24dab544681304b7f8a9dc073e7edaa4cf5 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.82e-06 | 192 | 21 | 4 | 3d0cb19f037f604253d7d728689aeaa94251e92b | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.82e-06 | 192 | 21 | 4 | df1545670370fb1010c567cd059c2783eab315f7 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.89e-06 | 194 | 21 | 4 | 60622bd2f75bfe4c37f721cb12f03dab33f2f58d | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.89e-06 | 194 | 21 | 4 | 6e13549f697f7478b34fe71f7dd9d63c5d3db22e | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.89e-06 | 194 | 21 | 4 | 89b706af2b25991fc2707eb24f49ba6ff3ae01f7 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 2.10e-06 | 199 | 21 | 4 | 30d3e8c0681ec11f86dd38c5f48d21187a1b4f90 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 2.14e-06 | 200 | 21 | 4 | 9b0916d8d07ac2bf1739f7be5296bf77ffee6094 | |
| ToppCell | Club-club-6|World / Class top | 6.27e-06 | 77 | 21 | 3 | 3653cf20b1b312578a54ffd33e75a8b92874f9bf | |
| ToppCell | Control-Fibroblasts-Mesothelial_FB|Control / group, cell type (main and fine annotations) | 3.68e-05 | 139 | 21 | 3 | e769beb031b262dd92c9605b07dbf3c29fb82520 | |
| ToppCell | 356C-Myeloid-Macrophage-FABP4+_Macrophage_3|356C / Donor, Lineage, Cell class and subclass (all cells) | 5.10e-05 | 155 | 21 | 3 | e1a20e88b9c0eaf7ca7004acc0eda096d1588563 | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(non-nasal)-Club_(non-nasal)_L.0.4.1.3|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.36e-05 | 167 | 21 | 3 | 8fede587572d465cb63f7828141a574185bbb819 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.47e-05 | 168 | 21 | 3 | 315ca578c945aeeb77acda2727f3e6db8b43f43e | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 6.94e-05 | 172 | 21 | 3 | 6c17a1e586a72d1bd80c20c06370429c61dc9f85 | |
| ToppCell | 356C-Myeloid-Macrophage-FABP4+_Macrophage_3|Macrophage / Donor, Lineage, Cell class and subclass (all cells) | 7.43e-05 | 176 | 21 | 3 | bfa1633e1b7a8a2f04d37fa07284fe9bc0199f46 | |
| ToppCell | 356C-Myeloid-Macrophage-FABP4+_Macrophage_3|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 7.56e-05 | 177 | 21 | 3 | 3d955ea938a1d2fb1b6d68d4997fd454bd632dfc | |
| ToppCell | 5'-GW_trimst-1-SmallIntestine-Epithelial-epithelial_progenitor_cell-Stem_cells|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 8.07e-05 | 181 | 21 | 3 | c7a220891567c7539ad5a9ac9db375f0de08ea00 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_Arw_fibro_(16)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 8.89e-05 | 187 | 21 | 3 | 5258674d0346e5c51a4b965efcdc1790c970845d | |
| ToppCell | metastatic_Lymph_Node-Fibroblasts-COL13A1+_matrix_FBs|metastatic_Lymph_Node / Location, Cell class and cell subclass | 8.89e-05 | 187 | 21 | 3 | e04fb35f2f5b120659d06b5ae427ab1ec56d5c36 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.18e-05 | 189 | 21 | 3 | a153b83314cf52808f685296cff8c95af3f4983d | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.62e-05 | 192 | 21 | 3 | dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708 | |
| ToppCell | LPS_only-Stromal_mesenchymal|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.62e-05 | 192 | 21 | 3 | 162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158 | |
| ToppCell | facs-Brain_Non-Myeloid-Cortex_-18m-Macroglial-astrocyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.62e-05 | 192 | 21 | 3 | d2161842a38146261847fc9061ba9322e0f087e0 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.62e-05 | 192 | 21 | 3 | ee085e04d5dcfb657522484ed20b8c1ddeccfe0c | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.76e-05 | 193 | 21 | 3 | fb28717fadd06c3840636d25409ce80c9254bd34 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Mesenchymal-stromal_related-FDC|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 9.91e-05 | 194 | 21 | 3 | f9fbb043411546d8c9e0321a64165d411f44aeb7 | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum-3m|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.91e-05 | 194 | 21 | 3 | ba529c051f248d29f4222f4bc9801ba233859093 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Mesenchymal-stromal_related|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.01e-04 | 195 | 21 | 3 | 1be9502577267ca2a04656a99d57e3e2f124d92e | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.04e-04 | 197 | 21 | 3 | fdb92985f7df0c280b87d3e43c2394e70786a2c7 | |
| ToppCell | facs-Brain_Non-Myeloid-Cortex-3m|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.05e-04 | 198 | 21 | 3 | a7e5de81eb7d3d23812c179a001adbaab1506596 | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Mesenchymal-fibroblastic-Stromal_4_(MMP1+)|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.05e-04 | 198 | 21 | 3 | 229588189825b1080181db9515185677b742c668 | |
| ToppCell | COVID-19-lung-Fibroblast|lung / Disease (COVID-19 only), tissue and cell type | 1.05e-04 | 198 | 21 | 3 | df3de77216f5c5d6141ec44d01c56b942f611838 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Mesenchymal-stromal_related-T_reticular|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.05e-04 | 198 | 21 | 3 | 5c96778cf5623c662c2259fe70f8665c14a161dd | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_only / Treatment groups by lineage, cell group, cell type | 1.07e-04 | 199 | 21 | 3 | fde2b65afde69f402f1b7b056eaa266e9fd5b227 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.07e-04 | 199 | 21 | 3 | 5d2e85e40b6b52b1809e680b952913d77215b3d0 | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.07e-04 | 199 | 21 | 3 | 8b86c69aaf60feff53aa782559cfece7342a23de | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.07e-04 | 199 | 21 | 3 | a7dd94b172c973a131a6792f8ccd9bfe44d984ac | |
| ToppCell | Tracheal-NucSeq|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations | 1.07e-04 | 199 | 21 | 3 | 94b94b17ca18b8dc27b91da1f2ccf89e03cc7035 | |
| ToppCell | distal-3-mesenchymal-Myofibroblast|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.07e-04 | 199 | 21 | 3 | 1f20addc0d138fec02ed6ca4c518169c568de263 | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts|LPS_only / Treatment groups by lineage, cell group, cell type | 1.07e-04 | 199 | 21 | 3 | 1a0add79f4e34078b3475eb11c85a4234bda197c | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Glial-Neuronal|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.07e-04 | 199 | 21 | 3 | 1bb5797e8e0552bf9b44bf4c958d1aa6dbe6c756 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.07e-04 | 199 | 21 | 3 | e1849505b92820a219c5a2c35492bdd55579fb48 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_perichondrial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.07e-04 | 199 | 21 | 3 | abd6117f8a3d7e798d8471c16d97b34aaf50fc9c | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic|LPS_only / Treatment groups by lineage, cell group, cell type | 1.07e-04 | 199 | 21 | 3 | 211c3a08f2d484ab7a3368006767289088f0d957 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.07e-04 | 199 | 21 | 3 | 9dd4b17fb8c70ab9e126b23b72600463f3db832d | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-Z|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.07e-04 | 199 | 21 | 3 | 6fb5f931e6217142de38c1fffc011e63bda4772b | |
| ToppCell | Biopsy_Other_PF-Mesenchymal-Myofibroblasts|Biopsy_Other_PF / Sample group, Lineage and Cell type | 1.08e-04 | 200 | 21 | 3 | e504570fd7eec1524c401b1cfa9d10822d80d994 | |
| ToppCell | Macroglial-Astrocytes-GFAP---|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.08e-04 | 200 | 21 | 3 | 88d66550781a3c9102ff7455f5cff6fb072943cd | |
| ToppCell | distal-mesenchymal-Myofibroblast-3|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.08e-04 | 200 | 21 | 3 | 069c8949b33ecfdb6da32992002d4060ff6082bc | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.08e-04 | 200 | 21 | 3 | 44a68bacdb3d5bf563bd35952176995850933a81 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Astrocyte-Astrocyte-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.08e-04 | 200 | 21 | 3 | 07d942803360e1a1e8e131d6e31c726dd0db1a0b | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.08e-04 | 200 | 21 | 3 | dc61016c61729f69649cfb21f6264e685ce83dea | |
| ToppCell | Macroglial-Astrocytes-GFAP-|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.08e-04 | 200 | 21 | 3 | d6a059b0ef763c281c60b1ac76da6079ea822f80 | |
| ToppCell | Macroglial-Astrocytes-GFAP--|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.08e-04 | 200 | 21 | 3 | 16269fa4adb28fc6ed032bbdba8781237dd0d249 | |
| ToppCell | Macroglial-Astrocytes-GFAP|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.08e-04 | 200 | 21 | 3 | 79634b1086934412ae92f259ab43554ce545008f | |
| ToppCell | Macroglial-Astrocytes-GFAP----L1-2|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.08e-04 | 200 | 21 | 3 | c6f43bbbd5df5f2c19ae385f1a6b6a330abede2f | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.08e-04 | 200 | 21 | 3 | b79628fd1386aa9a3b0e9fa81def0bc100c3c073 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.08e-04 | 200 | 21 | 3 | 3bdba9612cd7c612b76aa9abecc4a6529aabfc1c | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 1.08e-04 | 200 | 21 | 3 | bd8cf33502adea320e91ca2af14e1911d88ad374 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.08e-04 | 200 | 21 | 3 | 50ca6550998e461ef26dd670351060bd940765a8 | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_only / Treatment groups by lineage, cell group, cell type | 1.08e-04 | 200 | 21 | 3 | a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2 | |
| ToppCell | distal-mesenchymal-Myofibroblast|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.08e-04 | 200 | 21 | 3 | 61854a459385cd9295be37157a8f81a2c227dff3 | |
| ToppCell | Frontal_cortex-Macroglia-ASTROCYTE-Gja1-Gfap-_astrocytes_(Gja1)-|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 9.41e-04 | 97 | 21 | 2 | 0cd19f619f10a35d3107518aa83c0eda0572930a | |
| ToppCell | Frontal_cortex-Macroglia-ASTROCYTE-Gja1-Gfap-_astrocytes_(Gja1)|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 9.41e-04 | 97 | 21 | 2 | 031bc124739541b0b2591e1b6ef41f12adfd5c18 | |
| ToppCell | Frontal_cortex-Macroglia-ASTROCYTE-Gja1-Gfap-_astrocytes_(Gja1)--|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 9.41e-04 | 97 | 21 | 2 | 33330ac2de9e49d78b478f175068999235c9af25 | |
| ToppCell | lymphoid-T_cell-pro-T_cell|lymphoid / Lineage, cell class and subclass | 9.60e-04 | 98 | 21 | 2 | 4da11182885d5f2673e85bd9c5717939b0268427 | |
| ToppCell | Striatum-Macroglia-ASTROCYTE|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.41e-03 | 119 | 21 | 2 | 0583387cc4497cf991fa42a81f2f66d9c6b774eb | |
| ToppCell | Striatum-Macroglia-ASTROCYTE-Gja1|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.41e-03 | 119 | 21 | 2 | d47880ef1cff036192c43646a04fa8598dd7e1f4 | |
| ToppCell | Hippocampus-Macroglia-ASTROCYTE-Gja1-Astrocyte.Gja1.Nnat_(Nnat)|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.46e-03 | 121 | 21 | 2 | 8334a6b2ced1d6a4808458d6d4232d1b688ba28a | |
| ToppCell | Hippocampus-Macroglia-ASTROCYTE-Gja1-Astrocyte.Gja1.Nnat_(Nnat)--|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.46e-03 | 121 | 21 | 2 | 4b33eeed7b70da120133b14d42c104d2461d52dc | |
| ToppCell | Hippocampus-Macroglia-ASTROCYTE-Gja1-Astrocyte.Gja1.Nnat_(Nnat)-|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.46e-03 | 121 | 21 | 2 | a33e4ae0b0efb702db1b646ac0486e3b6ce48457 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Classical_Monocyte-Mono_c1-CD14-CCL3|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.46e-03 | 121 | 21 | 2 | b6dada0712b1f9793bc61e54ec7f10c9eaf53b86 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1-Airway|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.58e-03 | 126 | 21 | 2 | cde3b0fbdc324120e45e295eb171ee550653de47 | |
| ToppCell | control-Myeloid-CD14_Monocytes_3|control / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 1.89e-03 | 138 | 21 | 2 | 683cae06f710061d7d74c2f75eb511a2af55bacf | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-Mes-like-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.00e-03 | 142 | 21 | 2 | 5690eee2ce1ecd02e34eac4193578bd13c4228b9 | |
| ToppCell | Severe-B_intermediate-14|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 2.00e-03 | 142 | 21 | 2 | f9cbc266fcea19bec504be4f3a28d1173c6b2e3c | |
| ToppCell | LPS-IL1RA-Endothelial-Mes-Like-Alv_Cap|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.00e-03 | 142 | 21 | 2 | c3a5a80f78704d34db5df85d6e3e8fc84ff24268 | |
| ToppCell | Goblet-gob-2|World / Class top | 2.00e-03 | 142 | 21 | 2 | 9b058dc313d1f0edcd8473e342852632e17536a6 | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW09-Macroglial-Astrocyte|GW09 / Sample Type, Dataset, Time_group, and Cell type. | 2.00e-03 | 142 | 21 | 2 | 85e573616e54d41391b4ad8c3d38e4ca92112673 | |
| ToppCell | metastatic_Lymph_Node-Fibroblasts-COL13A1+_matrix_FBs|Fibroblasts / Location, Cell class and cell subclass | 2.00e-03 | 142 | 21 | 2 | 0e0f8bb956ff89dc98e8fa56f8acac33e01a26dd | |
| ToppCell | E12.5-Mesenchymal-mesenchymal_fibroblast-alveolar_fibroblast_Wnt2-pa|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.02e-03 | 143 | 21 | 2 | cc396b81a5e47d78c2d1cb49d682391376b63476 | |
| ToppCell | COVID-19_Mild-PLT_3|World / Disease Group and Platelet Clusters | 2.14e-03 | 147 | 21 | 2 | 9d3271aa735ddb6f32ab864d7afcfb0f8754383b | |
| ToppCell | Cerebellum-Macroglia-ASTROCYTE-Gja1|Cerebellum / BrainAtlas - Mouse McCarroll V32 | 2.25e-03 | 151 | 21 | 2 | 60aced0c1cc6b509b73308d03d58a3c44d712ef4 | |
| ToppCell | Cerebellum-Macroglia-ASTROCYTE|Cerebellum / BrainAtlas - Mouse McCarroll V32 | 2.25e-03 | 151 | 21 | 2 | 71841d2001200d1595c85c2b007ee20791a72927 | |
| ToppCell | mild_COVID-19_(asymptomatic)-CD8+_T_naive|World / disease group, cell group and cell class (v2) | 2.28e-03 | 152 | 21 | 2 | f944743f40ff6ed3a7a096dd53e12d3526c67c4d | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Transitional_Principal-Intercalated_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.34e-03 | 154 | 21 | 2 | ce4b1e878cd88065fbfd2df18caf19703fec37d8 | |
| ToppCell | mild_COVID-19_(asymptomatic)-CD8+_T_naive|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2) | 2.37e-03 | 155 | 21 | 2 | e2c901d5c9e42d25d7702e5e8fc19b06f7c817be | |
| ToppCell | Basal_cells-Donor_05|World / lung cells shred on cell class, cell subclass, sample id | 2.37e-03 | 155 | 21 | 2 | 30accc72a6a914ae0c4d52b373ea1c9a98efbf22 | |
| ToppCell | P28-Epithelial-epithelial_progenitor_cell-epi_progenitor|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.37e-03 | 155 | 21 | 2 | be575a0096415705dba425002247289ff8f89474 | |
| ToppCell | Control-Epithelial-Ionocyte|Epithelial / Disease state, Lineage and Cell class | 2.37e-03 | 155 | 21 | 2 | 4b9369b203a4d7071c56d3d8e6b450e9a0121c41 | |
| ToppCell | 10x_3'_v2v3-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia_independent-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.40e-03 | 156 | 21 | 2 | bb505f639dbcad2b788db62d6084c2cb4e884bec | |
| ToppCell | Children_(3_yrs)-Epithelial-basal_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.43e-03 | 157 | 21 | 2 | 6ee2692f705bdd93ba523dffaf2f0cd921b47e28 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c02-NCAM1|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.46e-03 | 158 | 21 | 2 | 4d997efc36fd8946775fe74dd9ac9ccd5ade64ff | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.49e-03 | 159 | 21 | 2 | fd7db2f7328cfefdc3ada2af91006d5a91d137e1 | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-myeloid-myeloid_granulocytic|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.49e-03 | 159 | 21 | 2 | 7b6370c9567da7d40541c6e243efa704ed7e90ae | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.49e-03 | 159 | 21 | 2 | aaf449c768d6fbb0a1bb47746ff3bdb7f9eb8914 | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-myeloid-myeloid_granulocytic-mast_cell|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.49e-03 | 159 | 21 | 2 | ecd1daa33549541aee3bf4e139ab6732efc8e74c | |
| Computational | Neighborhood of AF1Q | 3.38e-04 | 25 | 12 | 2 | GNF2_AF1Q | |
| Disease | response to anti-tuberculosis drug, drug-induced liver injury | 1.59e-06 | 3 | 22 | 2 | EFO_0004228, EFO_0007918 | |
| Disease | insulin resistance | 1.14e-05 | 59 | 22 | 3 | EFO_0002614 | |
| Disease | level of Triacylglycerol (51:3) in blood serum | 2.38e-05 | 10 | 22 | 2 | OBA_2045163 | |
| Disease | level of Ceramide (d40:1) in blood serum | 2.91e-05 | 11 | 22 | 2 | OBA_2045185 | |
| Disease | level of Diacylglycerol (18:1_18:1) in blood serum | 2.91e-05 | 11 | 22 | 2 | OBA_2045170 | |
| Disease | level of Diacylglycerol (18:1_18:2) in blood serum | 3.49e-05 | 12 | 22 | 2 | OBA_2045171 | |
| Disease | level of Triacylglycerol (53:3) in blood serum | 5.54e-05 | 15 | 22 | 2 | OBA_2045165 | |
| Disease | YKL40 measurement | 5.54e-05 | 15 | 22 | 2 | EFO_0004869 | |
| Disease | triacylglycerol 52:3 measurement | 5.54e-05 | 15 | 22 | 2 | EFO_0010415 | |
| Disease | triacylglycerol 54:6 measurement | 1.21e-04 | 22 | 22 | 2 | EFO_0010424 | |
| Disease | level of Phosphatidylethanolamine (16:0_18:2) in blood serum | 1.45e-04 | 24 | 22 | 2 | OBA_2045136 | |
| Disease | triacylglycerol 54:5 measurement | 2.60e-04 | 32 | 22 | 2 | EFO_0010423 | |
| Disease | triacylglycerol 52:5 measurement | 3.11e-04 | 35 | 22 | 2 | EFO_0010417 | |
| Disease | non-alcoholic fatty liver disease | 3.26e-04 | 182 | 22 | 3 | EFO_0003095 | |
| Disease | triacylglycerol 52:4 measurement | 3.29e-04 | 36 | 22 | 2 | EFO_0010416 | |
| Disease | cholesteryl esters to total lipids in medium LDL percentage | 3.48e-04 | 37 | 22 | 2 | EFO_0022252 | |
| Disease | triacylglycerol 50:3 measurement | 3.87e-04 | 39 | 22 | 2 | EFO_0010410 | |
| Disease | ciliopathy (implicated_via_orthology) | 4.07e-04 | 40 | 22 | 2 | DOID:0060340 (implicated_via_orthology) | |
| Disease | cholesteryl esters to total lipids in small LDL percentage | 4.49e-04 | 42 | 22 | 2 | EFO_0022255 | |
| Disease | triglycerides in large LDL measurement | 4.70e-04 | 43 | 22 | 2 | EFO_0022319 | |
| Disease | free cholesterol to total lipids in IDL percentage | 4.70e-04 | 43 | 22 | 2 | EFO_0022278 | |
| Disease | cholesteryl esters to total lipids in small HDL percentage | 4.70e-04 | 43 | 22 | 2 | EFO_0022254 | |
| Disease | free cholesterol to total lipids in very small VLDL percentage | 4.70e-04 | 43 | 22 | 2 | EFO_0022290 | |
| Disease | saturated fatty acids measurement | 5.15e-04 | 45 | 22 | 2 | EFO_0022304 | |
| Disease | triacylglycerol 54:4 measurement | 5.38e-04 | 46 | 22 | 2 | EFO_0010422 | |
| Disease | triglycerides to total lipids in medium LDL percentage | 6.36e-04 | 50 | 22 | 2 | EFO_0022334 | |
| Disease | polyunsaturated fatty acids to total fatty acids percentage | 6.36e-04 | 50 | 22 | 2 | EFO_0022303 | |
| Disease | cholesteryl esters to total lipids in IDL percentage | 6.36e-04 | 50 | 22 | 2 | EFO_0022247 | |
| Disease | triglycerides to total lipids in large LDL percentage | 6.62e-04 | 51 | 22 | 2 | EFO_0022331 | |
| Disease | polyunsaturated fatty acids to monounsaturated fatty acids ratio | 6.62e-04 | 51 | 22 | 2 | EFO_0022302 | |
| Disease | cholesterol to total lipids in small HDL percentage | 6.62e-04 | 51 | 22 | 2 | EFO_0022240 | |
| Disease | cholesterol to total lipids in small VLDL percentage | 6.62e-04 | 51 | 22 | 2 | EFO_0022242 | |
| Disease | total cholesterol measurement, diastolic blood pressure, triglyceride measurement, systolic blood pressure, hematocrit, ventricular rate measurement, glucose measurement, body mass index, high density lipoprotein cholesterol measurement | 6.62e-04 | 51 | 22 | 2 | EFO_0004340, EFO_0004348, EFO_0004468, EFO_0004530, EFO_0004574, EFO_0004612, EFO_0006335, EFO_0006336, EFO_0007928 | |
| Disease | triglycerides in HDL measurement | 7.15e-04 | 53 | 22 | 2 | EFO_0022317 | |
| Disease | free cholesterol to total lipids in small LDL percentage | 7.15e-04 | 53 | 22 | 2 | EFO_0022286 | |
| Disease | cholesteryl esters to total lipids in very large VLDL percentage | 7.15e-04 | 53 | 22 | 2 | EFO_0022258 | |
| Disease | systemic scleroderma (is_marker_for) | 7.15e-04 | 53 | 22 | 2 | DOID:418 (is_marker_for) | |
| Disease | triglycerides in medium HDL measurement | 7.42e-04 | 54 | 22 | 2 | EFO_0022321 | |
| Disease | total lipids in medium VLDL | 7.42e-04 | 54 | 22 | 2 | EFO_0022153 | |
| Disease | cholesterol to total lipids in very large VLDL percentage | 7.42e-04 | 54 | 22 | 2 | EFO_0022244 | |
| Disease | triglycerides in very large HDL measurement | 7.69e-04 | 55 | 22 | 2 | EFO_0022324 | |
| Disease | triglycerides in medium VLDL measurement | 7.69e-04 | 55 | 22 | 2 | EFO_0022155 | |
| Disease | cholesterol to total lipids in large HDL percentage | 7.69e-04 | 55 | 22 | 2 | EFO_0022234 | |
| Disease | phospholipids in medium HDL measurement | 7.69e-04 | 55 | 22 | 2 | EFO_0022295 | |
| Disease | triacylglycerol 52:2 measurement | 7.69e-04 | 55 | 22 | 2 | EFO_0010414 | |
| Disease | triglycerides in LDL measurement | 7.98e-04 | 56 | 22 | 2 | EFO_0022320 | |
| Disease | triglycerides in very large VLDL measurement | 7.98e-04 | 56 | 22 | 2 | EFO_0022325 | |
| Disease | triglycerides to total lipids in medium HDL percentage | 7.98e-04 | 56 | 22 | 2 | EFO_0022333 | |
| Disease | triglycerides in large VLDL measurement | 7.98e-04 | 56 | 22 | 2 | EFO_0022178 | |
| Disease | isoleucine measurement | 7.98e-04 | 56 | 22 | 2 | EFO_0009793 | |
| Disease | triglycerides in chylomicrons and extremely large VLDL measurement | 7.98e-04 | 56 | 22 | 2 | EFO_0022316 | |
| Disease | cholesterol to total lipids in large LDL percentage | 7.98e-04 | 56 | 22 | 2 | EFO_0022235 | |
| Disease | cholesteryl esters to total lipids in medium HDL percentage | 7.98e-04 | 56 | 22 | 2 | EFO_0022251 | |
| Disease | free cholesterol to total lipids in medium VLDL percentage | 8.26e-04 | 57 | 22 | 2 | EFO_0022284 | |
| Disease | triglycerides to total lipids in small VLDL percentage | 8.55e-04 | 58 | 22 | 2 | EFO_0022338 | |
| Disease | triglycerides in IDL measurement | 8.55e-04 | 58 | 22 | 2 | EFO_0022149 | |
| Disease | total lipids in medium HDL measurement | 8.55e-04 | 58 | 22 | 2 | EFO_0022310 | |
| Disease | free cholesterol in medium HDL measurement | 8.55e-04 | 58 | 22 | 2 | EFO_0022267 | |
| Disease | urate measurement, spine bone mineral density | 8.55e-04 | 58 | 22 | 2 | EFO_0004531, EFO_0007701 | |
| Disease | pre-eclampsia (is_marker_for) | 8.55e-04 | 58 | 22 | 2 | DOID:10591 (is_marker_for) | |
| Disease | triglycerides in VLDL measurement | 8.85e-04 | 59 | 22 | 2 | EFO_0022326 | |
| Disease | triglycerides to total lipids in small LDL percentage | 8.85e-04 | 59 | 22 | 2 | EFO_0022337 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| LFFRRPKASLPRVFV | 166 | Q9ULK5 | |
| FSPIVTLEPRRRKFH | 1216 | Q01484 | |
| LKQRKPRILFSPFFH | 121 | P41212 | |
| RRTFIKSVPPFLRTH | 116 | P36222 | |
| PPSRRKLFTFSHPVR | 661 | A4D2P6 | |
| PFLSRDPFHSLKRPR | 1426 | Q5VT52 | |
| HKHFRPIFTKVPRFN | 601 | Q6ZTR5 | |
| PFVFKLLLHRPFFRC | 136 | Q9UNQ2 | |
| IQTHRFPDRILPRKF | 596 | Q9Y4K4 | |
| HFRPFPIDIFIRRAI | 441 | Q8N323 | |
| EHPTPFLAFLRRVKT | 1526 | P23468 | |
| FIRIPIPTRRHTFRR | 136 | Q13393 | |
| SLARFFSHLLRRPPP | 81 | O76081 | |
| TLHLPTERFSPVRRF | 611 | Q9Y2K2 | |
| LPHRRPHFFFPKSRI | 211 | P10909 | |
| FKYLPISHPRFVRTI | 1101 | Q14690 | |
| RILFRHFFPKDKQPS | 56 | A0A1B0GUW6 | |
| SLFFLRIVHGRKSRP | 126 | Q9Y6N7 | |
| SRRKQLTFHRFPFSR | 16 | Q8WTV1 | |
| LTFHRFPFSRPELLK | 21 | Q8WTV1 | |
| KRSIFPIHPSFRIIA | 566 | A3KMH1 | |
| PFTRFLVPFTLHRKR | 16 | Q7L0Y3 | |
| RLPPFLIIHLKRFQF | 1071 | P35125 |